{
    "q": [
        {
            "docid": "175734_27",
            "document": "Local anesthetic . All LAs are membrane-stabilizing drugs; they reversibly decrease the rate of depolarization and repolarization of excitable membranes (like nociceptors). Though many other drugs also have membrane-stabilizing properties, not all are used as LAs (propranolol, for example). LA drugs act mainly by inhibiting sodium influx through sodium-specific ion channels in the neuronal cell membrane, in particular the so-called voltage-gated sodium channels. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Local anesthetic drugs bind more readily to sodium channels in an activated state, thus onset of neuronal blockade is faster in rapidly firing neurons. This is referred to as state-dependent blockade.",
            "score": 50.48617911338806
        },
        {
            "docid": "238839_10",
            "document": "Tetrodotoxin . The use of this toxin as a biochemical probe has elucidated two distinct types of voltage-gated sodium channels present in humans: the tetrodotoxin-sensitive voltage-gated sodium channel (TTX-s Na channel) and the tetrodotoxin-resistant voltage-gated sodium channel (TTX-r Na channel). Tetrodotoxin binds to TTX-s Na channels with a binding affinity of 5\u201315 nM, while the TTX-r Na channels bind TTX with low micromolar affinity. Nerve cells containing TTX-r Na channels are located primarily in cardiac tissue, while nerve cells containing TTX-s Na channels dominate the rest of the body.",
            "score": 47.64589500427246
        },
        {
            "docid": "33110155_3",
            "document": "HVCN1 . Voltage-gated hydrogen channel 1 is a voltage-gated proton channel that has been shown to allow proton transport into phagosomes and out of many types of cells including spermatozoa, electrically excitable cells and respiratory epithelial cells. The proton-conducting HVCN1 channel has only transmembrane domains corresponding to the S1-S4 voltage sensing domains (VSD) of voltage-gated potassium channels and voltage-gated sodium channels. Molecular simulation is consistent with a water-filled pore that can function as a \"water wire\" for allowing hydrogen bonded H to cross the membrane. However, mutation of Asp112 in human Hv1 results in anion permeation, suggesting that obligatory protonation of Asp produces proton selectivity. Quantum mechanical calculations show that the Asp-Arg interaction can produce proton selective permeation. The HVCN1 protein has been shown to exist as a dimer with two functioning pores. Like other VSD channels, HVCN1 channels conduct ions about 1000-fold slower than channels formed by tetrameric S5-S6 central pores.",
            "score": 41.219664096832275
        },
        {
            "docid": "14495617_7",
            "document": "Lacosamide . Lacosamide is a functionalized amino acid that produces activity in the maximal electroshock seizure (MES) test, that, like some other antiepileptic drugs (AEDs), are believed to act through voltage-gated sodium channels. Lacosamide enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels. This inactivation prevents the channel from opening, helping end the action potential. Many antiepileptic drugs, like carbamazepine or lamotrigine, slow the recovery from inactivation and hence reduce the ability of neurons to fire action potentials. Inactivation only occurs in neurons firing action potentials; this means that drugs that modulate fast inactivation selectively reduce the firing in active cells. Slow inactivation is similar but does not produce complete blockade of voltage gated sodium channels, with both activation and inactivation occurring over hundreds of milliseconds or more. Lacosamide makes this inactivation happen at less depolarized membrane potentials. This means that lacosamide only affects neurons which are depolarized or active for long periods of time, typical of neurons at the focus of epilepsy. Lacosamide administration results in the inhibition of repetitive neuronal firing, the stabilization of hyperexcitable neuronal membranes, and the reduction of long-term channel availability, but does not affect physiological function. Lacosamide has a dual mechanism of action. It also modulates collapsin response mediator protein 2 (CRMP-2), preventing the formation of abnormal neuronal connections in the brain.",
            "score": 45.53731036186218
        },
        {
            "docid": "20227419_5",
            "document": "Transmembrane channels . Ion channels are a type of transmembrane channel responsible for the passive transport of positively charged ions (sodium, potassium, calcium, hydrogen and magnesium) and negatively charged ions (chloride) and, can be either gated or ligand-gated channels. One of the best studied ion channels is the potassium ion channel. The potassium ion channel can allow rapid movement of potassium ions while being selective against sodium. Using X-ray diffraction data and atomic model computations a likely structure of the channel consists of a number of protein alpha-helixes forming an hourglass shaped pore with the narrowest point halfway through the membrane's lipid bilayer. To move through the channel the potassium ions must shed their aqueous matrix and enter a selectivity filter composed of carbonyl oxygens. The potassium ions pass through one atom at a time along five different cation (positively charged ion) binding sites.",
            "score": 48.47289323806763
        },
        {
            "docid": "25260082_9",
            "document": "Depolarizing prepulse . Since the Hodgkin\u2013Huxley model was first proposed in the 1950s, much has been learned concerning the structure and functionality of voltage-gated sodium channels. Although the exact three dimensional structure of the sodium channel remains unknown, its composition and the functionality of individual components have been determined. Voltage-gated sodium channels are large, multimeric complexes, composed of a single \u03b1 subunit and one or more \u03b2 subunits, an illustration of which may be observed in the adjacent image. The \u03b1 subunit folds into four homologous domains, each of which contain six \u03b1-helical transmembrane segments. The S segments of each domain serve as voltage sensors for activation. Each S segment consists of a repeating structure of one positively charged residue and two hydrophobic residues, and these combine to form a helical arrangement. When the channel is depolarized these S segments undergo a conformational change that widens the helical arrangement and opens the sodium-channel pore. Within milliseconds after the pore\u2019s opening, the intracellular loop that connects domains III and IV, binds to the channel\u2019s intracellular pore, inactivating the channel. Thus, by providing a depolarizing prepulse before a stimulus, there is a greater probability that the inactivating domains of the sodium channels have bound to their respective pores, reducing the stimulus induced sodium influx and the influence of the stimulus.",
            "score": 31.300501823425293
        },
        {
            "docid": "18983276_5",
            "document": "Channel blocker . To comprehend the mechanism of channel blockers, it is critical to understand the composition of ion channels. Their main function is to contribute to the resting membrane potential of a cell via the flow of ions through a cell membrane. To accomplish this task, ions must be able to cross the hydrophobic region of a lipid bilayer membrane, an unfavorable process. To assist in ion transport, ion channels form a hydrophilic pore through the membrane which allows for the usually unfavorable transfer of hydrophilic molecules. Various ion channels have varying mechanisms of function. They include: Molecules that act as ion channel blockers can be used in relation to any of these various channels. For example, sodium channels, which are essential to the production of action potentials, are affected by many different toxins. Tetrodotoxin (TTX), a toxin found in pufferfish, completely blocks sodium ion transportation by blocking the selectivity filter region of the channel. Much of the structure of the pores of ion channels has been elucidated from studies that used toxins to inhibit channel function.",
            "score": 46.07488250732422
        },
        {
            "docid": "53513088_12",
            "document": "Decarbamoylsaxitoxin . Decarbamoylsaxitoxin is a known neurotoxin, which mechanism is based on that of saxitoxin. Both namely bind to sodium channels, as shown in figure 3 Sodium channels contain negative residues at the top of their pore. These negatively charged residues are part of the filter for sodium. Decarbamoylsaxitoxin contains two guanidine substructures which can be protonated easily. Protonation of the guanidine substructures leads to a positive charge on the decarbamoylsaxitoxin and because of this positive charge the decarbamoylsaxitoxin can bind to the sodium channels. This binding to sodium channels prevents sodium passing through the channel. Because sodium passage is blocked, the channel cannot fulfill its function and it will be impossible to generate an action potential in the cell with the blocked sodium channels. There has been a study performed on which sodium channels are mainly targeted by the neurotoxin. This study showed that the neuromuscular transmission in the motor axon and the muscular membrane is targeted whereas the end-plate is left unaffected. It also showed that the atrioventicular node is the main target inside the heart. The consequences of decarbamoylsaxitoxin are paralysis and death.In vitro tests declared decarbamoylsaxitoxin more toxic as its brother saxitoxin. Although it is not entirely sure how this is caused, it can be speculated that it is caused by the alcohol group that is present on decarbamoylsaxitoxin instead of the amide group on saxitoxin. However, what can be concluded for sure is that decarbamoylsaxitoxin is converted into other compounds in the body or has trouble reaching the sodium channels. In vivo tests namely declared decarbamoylsaxitoxin half as toxic as saxitoxin.",
            "score": 51.88902306556702
        },
        {
            "docid": "18037036_3",
            "document": "Pilsicainide . Pilsicainide is a drug used clinically in Japan to treat cardiac arrhythmias. It functions by blocking the fast inward movement of sodium ions through the Nav1.5 sodium channel that contributes to the rapid depolarization characteristic of phase 0 in the cardiac action potential. Pilsicainide is a pure sodium channel blocker, meaning it does not significantly affect any other cardiac channels including potassium and calcium channels. Pilsicainide binds to a common site on the sodium channel through either intracellular or extracellular application(3). The affinity of pilsicainide for the sodium channel receptor and its rate of binding are dependent on the state of the channel. It has been proven to have a greater affinity for the receptor in its inactivated state as opposed to resting or open(4), thereby following the modulated receptor hypothesis(5). Binding of pilsicainide selectively inhibits the channel(6), preventing the movement of sodium ions into the cardiac cell. This decreases the rate of depolarization of the cell membrane as well as the action potential amplitude, but has no effect on the overall duration of the action potential(6). Suppression of the depolarization rate is use-dependent(7), and therefore inhibition increases with increased stimulation. Pilsicainide also causes delayed impulse conduction through the myocardium in a dose-dependent manner(8). The effects of pilsicainide have a slow rate of onset and offset resulting in a prolonged recovery time(9). This contributes to its potent blocking activity and its classification as a class 1c antiarrhythmic agent(10). A cardiac arrhythmia includes any abnormal heartbeat and can be manifested as tachycardia, bradycardia, or other irregular rhythms. Pilsicainide has been proven successful in treating both ventricular(11) and supraventricular arrhythmias with few adverse effects(12). It is especially effective in the treatment of atrial fibrillation. Atrial fibrillation is the most common type of arrhythmia(14). It may result from various heart abnormalities or may occur spontaneously in a seemingly healthy individual(15). Atrial fibrillation is characterized by rapid, disorganized electrical impulses in the atria resulting in depolarization of only a small group of myocardial cells. This prevents the atria from undergoing coordinated contraction, instead resulting in small fibrillations of the heart muscle. Re-entry occurs when an impulse does not die after activating the heart but instead returns to the atria and causes re-excitation(16). Simultaneous re-entry of multiple impulses with short wavelengths results in atrial fibrillation(17). Impulse wavelength is the product of the conduction velocity and the effective refractory period. Pilsicainide suppresses atrial conduction velocity but also increases the effective refractory period(18). Its effects on the refractory period are significantly more substantial, and therefore pilsicainide treatment results in an increased wavelength and termination of atrial fibrillation. A single oral dose of pilsicainide effectively restores normal sinus rhythm in patients with recent-onset atrial fibrillation and a healthy left ventricle. Long-term therapy with pilsicainide is successful in treating chronic atrial fibrillation).",
            "score": 51.072962522506714
        },
        {
            "docid": "29218_18",
            "document": "Sodium thiopental . Sodium thiopental is a member of the barbiturate class of drugs, which are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABA receptor channel is one of several representatives. This superfamily of ion channels includes the neuronal nAChR channel, the 5HT3R channel, the GlyR channel and others. Surprisingly, while GABA receptor currents are increased by barbiturates (and other general anesthetics), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds. For example, neuronal nAChR channels are blocked by clinically relevant anesthetic concentrations of both sodium thiopental and pentobarbital. Such findings implicate (non-GABA-ergic) ligand-gated ion channels, e.g. the neuronal nAChR channel, in mediating some of the (side) effects of barbiturates. The GABA receptor is an inhibitory channel that decreases neuronal activity, and barbiturates enhance the inhibitory action of the GABA receptor.",
            "score": 59.19086694717407
        },
        {
            "docid": "179962_3",
            "document": "Anticonvulsant . Conventional antiepileptic drugs may block sodium channels or enhance \u03b3-aminobutyric acid (GABA) function. Several antiepileptic drugs have multiple or uncertain mechanisms of action. Next to the voltage-gated sodium channels and components of the GABA system, their targets include GABA receptors, the GAT-1 GABA transporter, and GABA transaminase. Additional targets include voltage-gated calcium channels, SV2A, and \u03b12\u03b4. By blocking sodium or calcium channels, antiepileptic drugs reduce the release of excitatory glutamate, whose release is considered to be elevated in epilepsy, but also that of GABA. This is probably a side effect or even the actual mechanism of action for some antiepileptic drugs, since GABA can itself, directly or indirectly, act proconvulsively. Another potential target of antiepileptic drugs is the peroxisome proliferator-activated receptor alpha. The drug class was the 5th-best-selling in the US in 2007.",
            "score": 50.65769910812378
        },
        {
            "docid": "18983276_8",
            "document": "Channel blocker . Many different organic compounds can act as channel blockers despite channel specificity. Channels have evolved structures that, due to their membrane spanning regions, can discriminate between various ions or compounds. For example, some objects are too large for to fit into channels that are structurally specified to transport smaller objects, such as a potassium ion attempting to fit into a sodium channel. Conversely, some objects are too small to be properly stabilized by certain channel pores, such as a sodium ion attempting to pass through a potassium channel. In both cases, channel flux is not permitted. However, as long as a particular compound possesses adequate chemical affinity to a channel, that compound may be able to bind and block the channel pore. For example, TTX can bind and inactivate voltage-gated sodium channels, despite the fact that TTX is much larger and chemically different than sodium ions. Given the disparities in size and chemical properties between TTX and a sodium ion, this is an example of structure being used to block usually specific channels.",
            "score": 53.83474004268646
        },
        {
            "docid": "15303_2",
            "document": "Ion channel . Ion channels are pore-forming membrane proteins that allow ions to pass through the channel pore. Their functions include establishing a resting membrane potential, shaping action potentials and other electrical signals by gating the flow of ions across the cell membrane, controlling the flow of ions across secretory and epithelial cells, and regulating cell volume. Ion channels are present in the membranes of all excitable cells. Ion channels are one of the two classes of ionophoric proteins, along with ion transporters (including the sodium-potassium pump, sodium-calcium exchanger, and sodium-glucose transport proteins).",
            "score": 40.5768883228302
        },
        {
            "docid": "598586_9",
            "document": "Threshold potential . However, once a stimulus activates the voltage-gated sodium channels to open, positive sodium ions flood into the cell and the voltage increases. This process can also be initiated by ligand or neurotransmitter binding to a ligand-gated channel. More sodium is outside the cell relative to the inside, and the positive charge within the cell propels the outflow of potassium ions through delayed-rectifier voltage-gated potassium channels. Since the potassium channels within the cell membrane are delayed, any further entrance of sodium activates more and more voltage-gated sodium channels. Depolarization above threshold results in an increase in the conductance of Na sufficient for inward sodium movement to swamp outward potassium movement immediately. If the influx of sodium ions fails to reach threshold, then sodium conductance does not increase a sufficient amount to override the resting potassium conductance. If successful, the sudden influx of positive charge depolarizes the membrane, and potassium is delayed in re-establishing, or hyperpolarizing, the cell. Sodium influx depolarizes the cell in attempt to establish its own equilibrium potential (about +52 mV) to make the inside of the cell more positive relative to the outside.",
            "score": 35.57801175117493
        },
        {
            "docid": "1822196_5",
            "document": "Molecular neuroscience . Sodium channels were the first voltage-gated ion channels to be isolated in 1984 from the eel \"Electrophorus electricus\" by Shosaku Numa. The pufferfish toxin tetrodotoxin (TTX), a sodium channel blocker, was used to isolate the sodium channel protein by binding it using the column chromatography technique for chemical separation. The amino acid sequence of the protein was analyzed by Edman degradation and then used to construct a cDNA library which could be used to clone the channel protein. Cloning the channel itself allowed for applications such as identifying the same channels in other animals.  Sodium channels are known for working in concert with potassium channels during the development of graded potentials and action potentials. Sodium channels allow an influx of Na ions into a neuron, resulting in a depolarization from the resting membrane potential of a neuron to lead to a graded potential or action potential, depending on the degree of depolarization.",
            "score": 41.31915855407715
        },
        {
            "docid": "9773357_11",
            "document": "N-type calcium channel . N-type calcium voltage gated ion channels are permeable to calcium and are known to regulate neuronal excitability and the firing of action potentials in the neurons. These actions affect the transmission of neurotransmitters in nociceptive pathways. Nociceptive pathways are the neurons that are involved in pain perception, which typically arises from damage of the neurons or disease occurring in the nerves themselves. When action potentials in this pathway make it to the central terminals of the sensory neurons that are in the spinal cord, there is an influx of calcium that enters through the voltage-gated ion channels. This influx of calcium then triggers the release of the pro-nociceptive neurotransmitters. These neurotransmitters then bind to the receptors on the sensory neurons that cause a person to feel pain. Since these channels are able to influence the neurotransmitters in the body that cause a person to sense pain, voltage-gated ion channels that are permeable to calcium have also been found to be good targets for regulating chronic pain in patients who have difficulty finding effective treatment. A few of the conditions involving pain that are difficult to treat are acute pain, chronic inflammatory pain, and chronic neuropathic pain. These conditions are treated with medicine that has either been prone to becoming addictive to the patient, or can cause serious side effects, making the medicine controversial. <br>  <br> Studies have shown that N-type channels are particularly of interest in developing new medicine to help in treating chronic pain. N-type channels play a key role in being able to control the neurotransmission of pain in the spinal cord. Studies have shown that N-type channels are located in high amounts at the presynaptic terminals of neurons. They have a complex of proteins that form a pore with the \u02511Bsubunit (also known as CaV2.2) and an auxiliary \u02512\u03b4\u03b4 and \u03b2 subunits. When there is tissue damage, these subunits are regulated in the neuron, which helps to prove that these channels are involved in nociceptive transmission. When looking at the spinal cord, the distribution of N-type channels also coincides with the evidence of these channels having a role in the transmission of nociceptive information in the body. A new drug, Ziconotide, is being tested to alter N-type channels in order to treat these conditions of chronic pain. One of the newest medicines is an analgesic drug that works through targeting N-type calcium channels specifically in order to lessen the transmission of pain. Peptide \u0277\u0277-conotoxins are what bind to the N-type calcium channels in order to block ion permeation, which then blocks the influx of calcium and the transmission of the nociceptive responses. Neurons located in the posterior horn of the spinal cord experience \u0277\u0277-conotoxins that, when binding to the receptors, can inhibit the release of the pro-nociceptive neurotransmitters and neuromodulators that come from the central nerve terminals of the afferent neurons. This inhibition is what ultimately can stop the transmission of pain to the person from damaged cells. Ziconotide is an inorganic version of the \u0277\u0277-conotoxin, MVIIA. This medicine is able to inhibit the release of pro-nociceptive receptors, which will then block the transmission of pain.",
            "score": 54.862502574920654
        },
        {
            "docid": "6117921_8",
            "document": "Delta atracotoxin . Delta atracotoxin is responsible for the potentially lethal envenomation syndrome seen following funnel-web spider envenomation. d-Atracotoxins induce spontaneous, repetitive firing and prolongation of action potentials resulting in continuous acetylcholine neurotransmitter release from somatic and autonomic nerve endings. This will lead to slower voltage-gated sodium channel inactivation and a hyperpolarizing shift in the voltage-dependence of activation. This action is due to voltage-dependent binding to neurotoxin receptor site-3 in a similar, but not identical, fashion to scorpion a-toxins and sea anemone toxins. In the sea anemone and scorpion toxins, combinations of charged (especially cationic) and hydrophobic side-chains are important for binding to their receptor site (site 3) on the sodium channel. It will therefore be not surprising to find that the same applies to delta atracotoxin and versutoxin (a close homologue of delta atracotoxin). Delta atracotoxin presents three distinct charged patches on its surface, as well as a non-polar region centered on the 22-28 loop. Both of these structural features may play a role in its binding to the voltage-gated sodium channel, but further studies are necessary in defining which residues are important for interaction with the sodium channel so that a plausible model can be constructed of its binding site.",
            "score": 39.32966613769531
        },
        {
            "docid": "854573_6",
            "document": "Batrachotoxin . As a neurotoxin it affects the nervous system. Neurological function depends on depolarization of nerve and muscle fibres due to increased sodium ion permeability of the excitable cell membrane. Lipid-soluble toxins such as batrachotoxin act directly on sodium ion channels involved in action potential generation and by modifying both their ion selectivity and voltage sensitivity. Batrachotoxin (BTX) irreversibly binds to the Na+ channels which causes a conformational change in the channels that forces the sodium channels to remain open. Batrachotoxin not only keeps voltage-gated sodium channels open, but it also reduces the single-channel conductance. In other words, the toxin binds to the sodium channel and keeps the membrane permeable to sodium ions in an all or none manner.",
            "score": 43.46803379058838
        },
        {
            "docid": "32586493_7",
            "document": "Tefluthrin . Pyrethroid insecticides, and therefore also tefluthrin, influence the voltage-gated sodium channels of organisms. The sodium channels are heteromultimeric complexes consisting of one large \ud835\udefc-subunit and two smaller \ud835\udefd-subunits. The binding site of tefluthrin is on the \ud835\udefc-subunit, which also forms the pore of the channel. Tefluthrin alters the functioning of the voltage-gated sodium channels by blocking the inactivation and slowing the deactivation of the channels. This results in persistent and prolonged activation of sodium channels and inflow of sodium. However, there are many different forms of sodium channels. In mammals 9 different sodium channel \ud835\udefc-subunits have been identified (named Nav1.1-Nav1.9). The channel isoforms differ in affinity for tefluthrin, for example the Nav1.6 is at least 15-fold more sensitive than the Nav1.2 isoform. Also the action of tefluthrin is stereoselective. The cis isomer is up to 10-fold more toxic than the trans isomer, and also the binding differs between both isomers.",
            "score": 44.781797647476196
        },
        {
            "docid": "18983276_13",
            "document": "Channel blocker . Channel blockers are essential in the field of anesthetics. Sodium channel inhibitors are used as both antiepileptics and antiarrhythmics, as they can inhibit the hyper-excitable tissues in a patient. Introducing specific sodium channel blockers into a tissue allows for the preferential binding of the blocker to sodium channels, which results in an ultimate inhibition of the flow of sodium into the tissue. Over time, this mechanism leads to an overall decrease in tissue excitation. Prolonged hyperpolarization interrupts normal channel recovery and allows for constant inhibition, providing dynamic control of the anesthetics in a given setting.",
            "score": 39.93731904029846
        },
        {
            "docid": "9773355_11",
            "document": "P-type calcium channel . There are therapeutics used clinically which can effect the activity of P-type calcium channels. However, the primary target of these therapeutics are not thought to be P-type channels. For example, calcium antagonists, which are used to treat coronary heart disease, hypertension, and cardiac arrhythmia, act by inhibiting L-type or T-type calcium channels. Some of these calcium antagonists include verapamil, diltiazem, amlodipine, benidipine, cilnidipine, nicardipine, and barnidipine. Although their main target is not P-type channels, these calcium antagonists also act to block the function of P-type channels. Moreover, flunarizine is another calcium antagonist which is used to treat migraines. Its main targets are voltage-gated calcium channels and sodium channels. Flunarizine inhibits the P-type channels that are located in the neocortical slices. It works to inhibit the inward flux of calcium. The migraines that it helps to prevent are due to mutations within the \"cacna1a\" gene of the P-type channel subunit. Also, compounds that block P-type channels are shown to help with seizures. Epileptic seizures are caused by increased neurotransmission, which is partially a result of P-type channels. Compounds such as levetiracetam, lamotrigine, and carbamazepine are known to block the P-type channels, which have helped to decrease the occurrence of seizures. Overall, there are various non-selective calcium channel blockers that help alleviate symptoms of hypertension, schizophrenia, cardiac arrhythmia, epilepsy, pain, asthma, bradycardia, angina pectoris and Alzheimer's disease. Although many of the therapeutic compounds' main target is not P-type channels, further research needs to determine if the clinical effects of these compounds are also influenced by the P-type channel blockage.",
            "score": 62.087058544158936
        },
        {
            "docid": "9773355_15",
            "document": "P-type calcium channel . Levetiracetam is an anti-epileptic drug than can be used to treat partial and generalized seizures. Levetiracetam inhibits P/Q channel-mediated glutamate release and decreases the excitatory post synaptic currents of both AMPA and NMDA receptors in the hippocampus, specifically the dentate gyrus, which is known to propagate seizure activities. The inhibition of glutamate release results in an anti-epileptic response in patients because it decreases the excitatory postsynaptic current. There are many different types of calcium channels, so to prove that the P/Q type calcium channels are directly involved, a P/Q type voltage gated calcium channel inhibitor, omega-agatoxin TK, was used to block the channel. When blocked, patients no longer benefited from the anti-epileptic effects from the drugs. When blockers for L type and N type calcium channels were used, the effects of Levetiracetam were still seen. This is strong evidence that the P/Q type calcium channels are involved in the Levetiracetam treatment which allow for relief from seizures.",
            "score": 60.38640356063843
        },
        {
            "docid": "9773357_2",
            "document": "N-type calcium channel . N-type calcium channels are voltage gated calcium channels that are distributed throughout the entire body. These channels are high voltage activated channels composed of alpha-1B subunits. The alpha subunit forms the pore through which the calcium enters and helps to determine most of the channel's properties. The alpha subunit is also known as the calcium channel/voltage dependent/N type, alpha 1 subunit (CACNA1B), or calcium voltage-gated channel subunit alpha1 B. The subunit is essential to modulate neurotransmitter release. They also contain associated subunits such as \u03b21, \u03b23, \u03b24, \u03b12\u03b4, and possibly \u03b3. These channels are known for their importance in the nervous system. They play a small role in the migration of immature neurons before the establishment of their mature synapses, and they are critically involved in the release of neurotransmitters, which is also similar to another type of calcium channels, known as P-type calcium channels. N-type calcium channels are targets for the development of drugs to relieve chronic and neuropathic pain. They are also used for the treatment of hypertension, Autism Spectrum Disorder, Osteoarthritis, and other medical diagnoses. Additionally, N-type calcium channels have known functions in the kidney, and heart. There are many known N-type calcium channel blockers, that function to inhibit channel activity, but with the most notable blocker as \u03c9-Conotoxins. Blockers, like \u03c9-Conotoxins, can interfere with many different therapeutic processes.",
            "score": 44.787129521369934
        },
        {
            "docid": "1349300_20",
            "document": "Cyclic nucleotide\u2013gated ion channel . By measuring the currents activated in excised inside-out membrane patches upon superfusion with varying ligand concentrations, the ligand sensitivity and selectivity of both endogenously and exogenously expressed CNG channels have been studied. All native CNG channels react to both cAMP and cGMP, but smaller concentrations of cGMP than of cAMP are needed to activate and open the channels. CNG channels are sharply selective between cGMP and cAMP in rods and cones, whereas in OSNs, the channels respond equally well to both ligands. CNG channels found in OSNs are much more sensitive to both cGMP and cAMP than photoreceptor CNG channels. Studies of dose response relations showed that channel activation is greatly dependent on cGMP concentration; several cGMP molecules bind to the channel in a cooperative manner. Since each subunit contains a single cNMP-binding site, and homomeric and heteromeric channels most likely form a tetrameric complex, a maximum of four ligand molecules can bind to the channel. Selectivity can be achieved by differential control of the affinity for binding of the ligand, efficacy of gating, or a combination of both. Binding affinity means how tightly cyclic nucleotides bind to the channel. Efficacy refers to the ability of ligand to activate and open the channel once it is bound. Although these processes are useful in understanding selectivity, they are inextricably coupled to each other that it is very difficult to experimentally separate one from another.",
            "score": 50.9454060792923
        },
        {
            "docid": "14795539_9",
            "document": "Plakophilin-2 . There are data to support molecular crosstalk between plakophilin-2 and proteins involved in mechanical junctions in cardiomyocytes, including connexin 43, the major component of cardiac gap junctions; the voltage-gated sodium channel Na(V)1.5 and its interacting subunit, ankyrin G; and the K(ATP). Decreased expression of plakophilin-2 via siRNA leads to a decrease in and redistribution of connexin 43 protein, as well as a decrease in coupling of adjacent cardiomyocytes. Studies also showed that GJA1 and plakophilin-2 are components in the same biomolecular complex. Plakophilin-2 also associates with Na(V)1.5, and knockdown of plakophilin-2 in cardiomyocytes alters sodium current properties as well as velocity of action potential propagation. It has also been demonstrated that plakophilin-2 associates with an important component of the Na(V)1.5 complex, ankyrin G, and loss of ankyrin G via siRNA downregulation mislocalized plakophilin-2 and connexin 43 in cardiac cells, which was coordinate with decreased electrical coupling of cells and decreased adhesion strength. These studies were further supported by an investigation in a mouse model harboring a \"PKP2\"-heterozygous null mutation, which showed decreased Na(V)1.5 amplitude, as well as a shift in gating and kinetics; pharmacological challenge also induced ventricular arrhythmias. These findings further support the notion that desmosomes crosstalk with sodium channels in the heart, and suggest that the risk of arrhythmias in patients with \"PKP2\" mutations may be unveiled with pharmacological challenge. Evidence has also shown that plakophilin-2 binds to the K(ATP) channel subunit, Kir6.2, and that in cardiomyocytes from haploinsufficient \"PKP2\" mice, K(ATP) channel current density was \u223c40% smaller and regional heterogeneity of K(ATP) channels was altered, suggesting that plakophilin-2 interacts with K(ATP) and mediates crosstalk between intercellular junctions and membrane excitability.",
            "score": 48.724987506866455
        },
        {
            "docid": "518565_4",
            "document": "Hyperpolarization (biology) . Voltage gated ion channels respond to changes in the membrane potential. Voltage gated potassium, chloride and sodium channels are key component for generating the action potential as well as hyper-polarization. These channels work by selecting an ion based on electrostatic attraction or repulsion allowing the ion to bind to the channel. This releases the water molecule attached to the channel and the ion is passed through the pore. Voltage gated sodium channels open in response to a stimulus and close again. This means the channel either is open or not, there is no part way open. Sometimes the channel closes but is able to be reopened right away, known as channel gating, or it can be closed without being able to be reopened right away, known as channel inactivation.",
            "score": 40.550814151763916
        },
        {
            "docid": "23965432_4",
            "document": "Gating (electrophysiology) . The name 'gating' derives from the idea that an ion channel protein includes a pore that is guarded by a gate or several gates, and the gate(s) must be in the open position for any ions to pass through the pore. A variety of cellular changes can trigger gating, depending on the ion channel, including changes in voltage across the cell membrane (voltage-gated ion channels), drugs or hormones interacting with the ion channel (ligand-gated ion channels), changes in temperature, stretching or deformation of the cell membrane, addition of a phosphate group to the ion channel (phosphorylation), and interaction with other molecules in the cell (e.g., G proteins). The rate at which any of these gating processes occurs in response to these triggers are known as the 'kinetics of gating.' Some drugs and many ion channel toxins act as 'gating modifiers' of voltage-gated ion channels by changing the kinetics of gating.",
            "score": 43.41635751724243
        },
        {
            "docid": "51933345_13",
            "document": "Kalkitoxin . Kalkitoxin may activate the NMDA receptor. It also blocks the voltage-gated sodium channel and the electron transport chain (ETC) complex 1. It remains unknown how exactly kalkitoxin binds to the voltage-gated sodium channel. Neurotoxin sit 1 and 2 have been ruled out as possible binding sites, whereas neurotoxin site 7 is suggested as binding site for kalkitoxin. This is probable, because there is inhibition of the channel by kalkitoxin when deltamethrin, which has positive allosteric effects, is present. This could be because molecular determinants for binding are similar in kalkitoxin and deltamethrin.",
            "score": 40.81783986091614
        },
        {
            "docid": "284842_7",
            "document": "Grayanotoxin . Experiments utilizing squid axonal membranes indicate that sodium channel binding likely occurs on the internal face of the neuron. Additionally, grayanotoxin only binds to the activated conformation of sodium channels. Normally, voltage gated sodium channels are activated (opened) only when the cell membrane potential reaches a specific threshold voltage. This activated conformation allows for an influx of sodium ions resulting in cell depolarization, followed by the firing of an action potential. At the peak of the action potential, voltage-gated sodium channels are quickly inactivated and are only reset once the cell has repolarized to resting potential. When grayanotoxin is present, binding induces further conformational changes that prevent sodium channel inactivation and lead to a prolonged depolarization. Due to its transient ability to activate channels and increase membrane permeability to sodium ions, grayanotoxin is classified as a reversible Na\"\"1.\"x\" agonist.",
            "score": 36.17562747001648
        },
        {
            "docid": "1610581_5",
            "document": "Voltage-gated calcium channel . The \u03b1 subunit pore (~190 kDa in molecular mass) is the primary subunit necessary for channel functioning in the HVGCC, and consists of the characteristic four homologous I\u2013IV domains containing six transmembrane \u03b1-helices each. The \u03b1 subunit forms the Ca selective pore, which contains voltage-sensing machinery and the drug/toxin-binding sites. A total of ten \u03b1 subunits that have been identified in humans: \u03b1 subunit contains 4 homologous domains (labeled I\u2013IV), each containing 6 transmembrane helices (S1\u2013S6). This arrangement is analogous to a homo-tetramer formed by single-domain subunits of voltage-gated potassium channels (that also each contain 6 TM helices). The 4-domain architecture (and several key regulatory sites, such as the EF hand and IQ domain at the C-terminus) is also shared by the voltage gated sodium channels, which are thought to be evolutionary related to VGCCs. The transmembrane helices from the 4 domains line up to form the channel proper; S5 and S6 helices are thought to line the inner pore surface, while S1\u20134 helices have roles in gating and voltage sensing (S4 in particular). VGCCs are subject to rapid inactivation, which is thought to consist of 2 components: voltage-gated (VGI) and calcium-gated (CGI). These are distinguished by using either Ba or Ca as the charge carrier in the external recording solution (\"in vitro\"). The CGI component is attributed to the binding of the Ca-binding signaling protein calmodulin (CaM) to at least 1 site on the channel, as Ca-null CaM mutants abolish CGI in L-type channels. Not all channels exhibit the same regulatory properties and the specific details of these mechanisms are still largely unknown.",
            "score": 36.55436813831329
        },
        {
            "docid": "2879958_2",
            "document": "Sodium channel . Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (\"Voltage-gated\", \"voltage-sensitive\", or \"voltage-dependent\" sodium channel also called \"VGSCs\" or \"Nav channel\") or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels).",
            "score": 40.508341789245605
        },
        {
            "docid": "18608933_13",
            "document": "Sodium channel blocker . Class Ib antiarrhythmic agents are sodium channel blockers. They have fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. Class Ib agents shorten the action potential duration and reduce refractoriness. These agents will decrease V in partially depolarized cells with fast response action potentials. They either do not change the action potential duration, or they may decrease the action potential duration. Class Ib drugs tend to be more specific for voltage gated Na channels than Ia. Lidocaine in particular is highly frequency dependent, in that it has more activity with increasing heart rates. This is because lidocaine selectively blocks Na channels in their open and inactive states and has little binding capability in the resting state.",
            "score": 41.167158126831055
        }
    ],
    "r": [
        {
            "docid": "9773355_11",
            "document": "P-type calcium channel . There are therapeutics used clinically which can effect the activity of P-type calcium channels. However, the primary target of these therapeutics are not thought to be P-type channels. For example, calcium antagonists, which are used to treat coronary heart disease, hypertension, and cardiac arrhythmia, act by inhibiting L-type or T-type calcium channels. Some of these calcium antagonists include verapamil, diltiazem, amlodipine, benidipine, cilnidipine, nicardipine, and barnidipine. Although their main target is not P-type channels, these calcium antagonists also act to block the function of P-type channels. Moreover, flunarizine is another calcium antagonist which is used to treat migraines. Its main targets are voltage-gated calcium channels and sodium channels. Flunarizine inhibits the P-type channels that are located in the neocortical slices. It works to inhibit the inward flux of calcium. The migraines that it helps to prevent are due to mutations within the \"cacna1a\" gene of the P-type channel subunit. Also, compounds that block P-type channels are shown to help with seizures. Epileptic seizures are caused by increased neurotransmission, which is partially a result of P-type channels. Compounds such as levetiracetam, lamotrigine, and carbamazepine are known to block the P-type channels, which have helped to decrease the occurrence of seizures. Overall, there are various non-selective calcium channel blockers that help alleviate symptoms of hypertension, schizophrenia, cardiac arrhythmia, epilepsy, pain, asthma, bradycardia, angina pectoris and Alzheimer's disease. Although many of the therapeutic compounds' main target is not P-type channels, further research needs to determine if the clinical effects of these compounds are also influenced by the P-type channel blockage.",
            "score": 62.087059020996094
        },
        {
            "docid": "9773355_15",
            "document": "P-type calcium channel . Levetiracetam is an anti-epileptic drug than can be used to treat partial and generalized seizures. Levetiracetam inhibits P/Q channel-mediated glutamate release and decreases the excitatory post synaptic currents of both AMPA and NMDA receptors in the hippocampus, specifically the dentate gyrus, which is known to propagate seizure activities. The inhibition of glutamate release results in an anti-epileptic response in patients because it decreases the excitatory postsynaptic current. There are many different types of calcium channels, so to prove that the P/Q type calcium channels are directly involved, a P/Q type voltage gated calcium channel inhibitor, omega-agatoxin TK, was used to block the channel. When blocked, patients no longer benefited from the anti-epileptic effects from the drugs. When blockers for L type and N type calcium channels were used, the effects of Levetiracetam were still seen. This is strong evidence that the P/Q type calcium channels are involved in the Levetiracetam treatment which allow for relief from seizures.",
            "score": 60.38640594482422
        },
        {
            "docid": "41564423_4",
            "document": "Local anesthetic nerve block . Lidocaine preferentially binds to the inactivated state of voltage-gated sodium channels, but has also been found to bind potassium channels, G protein-coupled receptors, NMDA receptors, and calcium channels \"in vitro\". The duration of the block is mostly influenced by the amount of time the anesthetic is near the nerve. Lipid solubility, blood flow in the tissue, and presence of vasoconstrictors with the anesthetic all play a role in this. A higher lipid solubility makes the anesthetic more potent and have a longer duration of action; however, it also increases the toxicity of the drug.",
            "score": 59.47420120239258
        },
        {
            "docid": "29218_18",
            "document": "Sodium thiopental . Sodium thiopental is a member of the barbiturate class of drugs, which are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABA receptor channel is one of several representatives. This superfamily of ion channels includes the neuronal nAChR channel, the 5HT3R channel, the GlyR channel and others. Surprisingly, while GABA receptor currents are increased by barbiturates (and other general anesthetics), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds. For example, neuronal nAChR channels are blocked by clinically relevant anesthetic concentrations of both sodium thiopental and pentobarbital. Such findings implicate (non-GABA-ergic) ligand-gated ion channels, e.g. the neuronal nAChR channel, in mediating some of the (side) effects of barbiturates. The GABA receptor is an inhibitory channel that decreases neuronal activity, and barbiturates enhance the inhibitory action of the GABA receptor.",
            "score": 59.19086837768555
        },
        {
            "docid": "18983276_9",
            "document": "Channel blocker . A channel block can be induced by many different types of organic compounds as long as they can bind to some portion of the target channel's pore. The kinetics of channel blockers are primarily understood though their use as anesthetics. Local anesthetics work by inducing a phasic block state in the targeted neurons. Initially, open channel blockers do not effectively prevent action potentials, as few channels are blocked and the blocker itself can be released from the channel either quickly or slowly depending on its characteristics. However, phasic blocks occur as repeated depolarization increases blockers\u2019 affinity for channels in the neuron.The combination of an increase in available channels and the change in channel conformation to increase blocker binding affinity are responsible for this action.",
            "score": 58.28804397583008
        },
        {
            "docid": "36080526_17",
            "document": "KcsA potassium channel . Due to the high sequence similarity between the pore of KcsA and other eukaryotic K ion channel proteins, KcsA has provided important insight into the behavior of other important voltage conducting proteins such as the drosophilla-derived \"Shaker\" and the human \"hERG\" potassium channel. KcsA has been used in mutagenesis studies to model the interactions between hERG and various drug compounds. Such tests can screen for drug-hERG channel interactions that cause acquired long QT syndrome, are essential for determining the cardiac safety of new medications. In addition, homology models based on the closed state KcsA crystal structure have been generated computationally to construct a multiple state representation of the hERG cardiac K channel. Such models reveal the flexibility of the hERG channel and can consistently predict the binding affinity of a set of diverse ion channel-interacting ligands. Analysis of the complex ligand-hERG structures can be used to guide the synthesis of drug analogs with reduced hERG liability, based on drug structure and docking potential.",
            "score": 56.873939514160156
        },
        {
            "docid": "31276014_4",
            "document": "Celivarone . The specific molecular changes involved in arrhythmias depend on the nature of the problem. Ion channel mutations can alter protein conformation, and so change the amount of current flowing through these channels. Due to changes in amino acids and binding domains, mutations may also affect the ability of these channels to respond to physiological changes in cardiac demand. Mutations resulting in loss of function of K channels can result in delayed repolarization of the cardiac muscle cells. Similarly, gain of function of Na and Ca channels results in delayed repolarization, and Ca overload causing increased Ca binding to cardiac troponin C, more actin-myosin interactions and causing an increased contractility, respectively. Mutations cause many arrhythmic conditions, including atrial fibrillation (AF), atrial flutter (AFl), and ventricular fibrillation (V-Fib). Arrhythmias can also be induced by altered activity of the vagus nerve and activation of \u03b2 adrenergic receptors.",
            "score": 56.55511474609375
        },
        {
            "docid": "9773357_10",
            "document": "N-type calcium channel . N-type calcium channels have been connected to a variety of different clinical diagnoses. The alteration of N-type calcium channels in therapeutic processes occurs in four major ways; through the blockage of N-type calcium channel peptides, interference of the flow of ions through the channel itself, activation of G-protein coupled signaling, and interference of the G-protein pathways. They are most commonly linked to therapeutic treatment of chronic pain. Studies have shown that the intrathecal injection of calcium channel inhibitors such as Ziconotide, to block the N-type calcium channels, have produced alleviation of intractable pain. Administering N-type peptide blockers via injection into the spinal canal (intrathecal injection) allows the drugs to reach the cerebral spinal fluid where the channels are located. The use of blockers to inhibit the N-type calcium channels have produced alleviation of chronic pain from a variety of different diseases. For example, blockade of the N-type calcium channel is a potential therapeutic strategy for the treatment of alcoholism using N-type channel antagonists. Because prolonged alcohol exposure over time has been known to increase N-type channel function, experiments have been performed to determine the effect inhibiting them has on alcohol addiction. Studies have shown that using N-type antagonists to decrease channel activity has shown reduced voluntary consumption of alcohol. <br> <br> Studies have also shown that N-type peptide blockers have been used to relieve pain that results from osteoarthritis, hypertension, diabetic neuropathy. It has also been known to be used to aid in relief of pain associated with cancer and can be used for patients actively battling cancer. Studies are being done to see if the treatment may also be used for those survivors still experiencing chronic pain. Also, due to the N-type calcium channel being intrinsic to neurotransmitter release and excitability, they can be regulated via GPCR signaling using Analgesic opioid drugs to relieve pain. This is done by modulating the sensory transmitter release and subsequently lessening the feelings of pain and cancer. However, the use of intrathecally injected N-type channel blockers has proven to be more beneficial than common opioid remedies because there are less negative side effects associated. <br> <br> The Cav2.2 channel inhibitor, Ziconotide, for example, is the only drug on the market as of now that directly targets the n-type channel and its conotoxin peptide. N-type calcium channels have also been associated with several known diseases as well. For example, mutations in the CACNA1B gene have been associated with Myoclonus-Dystonia syndrome, an unusual hyperkinetic movement disorder with muscular contractile symptoms. This can be explained by the fact that the channel is mutated with an increase in current flow, subsequently causing hyperexcitability. It has also been linked to cardiac arrhythmia, as increased excitability can cause tachycardia. Issues with the alpha subunit of the N-type calcium channel . Duplication of the CACNA1B gene has also been linked to cases of the Autism Spectrum Disorder as well as psychiatric diseases such as bipolar disorder and schizophrenia.",
            "score": 56.404563903808594
        },
        {
            "docid": "16313420_4",
            "document": "Tedisamil . Tedisamil acts to restore normal electrical rhythm in the heart by prolonging the inactivation phase of the muscle. Both atrial and ventricular repolarization is lengthened by tedisamil by blocking multiple potassium channels including the transient outward (Ito), the adenosine triphosphate-dependent (IK-ATP), and the delayed rectifier potassium currents (IKr and IKs). Tedisamil action is dose dependent as currents are blocked longer and more effectively at higher concentrations. Tedisamil activity is greatest on Ito and acts by binding to the channel in its open configuration. This produces a blocked state and delays its inactivation. To restore normal function, tedisamil must unbind from the channel so that it can inactivate and eventually reopen. Similar mechanisms have been observed on the IKr and IKs currents. In both Ito and delayed rectifier channels, the tedisamil binding site appears to be internal as both binding and unbinding occur more effectively when tedisamil is applied inside the cell. Tedisamil also appears to provide specific, single channel blocking of IK-ATP at high concentrations. As the potassium channels are responsible for restoring the resting membrane potential during an action potential, lengthening their inactivation will stop the cycle of fibrillation by preventing muscle contraction until all ion channels are available to open. Regular use of tedisamil will prevent further fibrillation and restore normal electrical rhythm. Tedisamil\u2019s antiarrythmic activity also appears to be supported by inhibiting sodium currents in cardiac muscle. However this is only observed at concentrations above 20\u03bcM, concentrations 20-fold higher than required for potassium channel blocks.",
            "score": 55.659175872802734
        },
        {
            "docid": "1157843_2",
            "document": "Procainamide . Procainamide is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is classified by the Vaughan Williams classification system as class Ia; thus it is a sodium channel blocker of cardiomyocytes. In addition to blocking the \"I\" current, it inhibits the \"I\" rectifier K+ current. Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.",
            "score": 55.13432693481445
        },
        {
            "docid": "9773357_11",
            "document": "N-type calcium channel . N-type calcium voltage gated ion channels are permeable to calcium and are known to regulate neuronal excitability and the firing of action potentials in the neurons. These actions affect the transmission of neurotransmitters in nociceptive pathways. Nociceptive pathways are the neurons that are involved in pain perception, which typically arises from damage of the neurons or disease occurring in the nerves themselves. When action potentials in this pathway make it to the central terminals of the sensory neurons that are in the spinal cord, there is an influx of calcium that enters through the voltage-gated ion channels. This influx of calcium then triggers the release of the pro-nociceptive neurotransmitters. These neurotransmitters then bind to the receptors on the sensory neurons that cause a person to feel pain. Since these channels are able to influence the neurotransmitters in the body that cause a person to sense pain, voltage-gated ion channels that are permeable to calcium have also been found to be good targets for regulating chronic pain in patients who have difficulty finding effective treatment. A few of the conditions involving pain that are difficult to treat are acute pain, chronic inflammatory pain, and chronic neuropathic pain. These conditions are treated with medicine that has either been prone to becoming addictive to the patient, or can cause serious side effects, making the medicine controversial. <br>  <br> Studies have shown that N-type channels are particularly of interest in developing new medicine to help in treating chronic pain. N-type channels play a key role in being able to control the neurotransmission of pain in the spinal cord. Studies have shown that N-type channels are located in high amounts at the presynaptic terminals of neurons. They have a complex of proteins that form a pore with the \u02511Bsubunit (also known as CaV2.2) and an auxiliary \u02512\u03b4\u03b4 and \u03b2 subunits. When there is tissue damage, these subunits are regulated in the neuron, which helps to prove that these channels are involved in nociceptive transmission. When looking at the spinal cord, the distribution of N-type channels also coincides with the evidence of these channels having a role in the transmission of nociceptive information in the body. A new drug, Ziconotide, is being tested to alter N-type channels in order to treat these conditions of chronic pain. One of the newest medicines is an analgesic drug that works through targeting N-type calcium channels specifically in order to lessen the transmission of pain. Peptide \u0277\u0277-conotoxins are what bind to the N-type calcium channels in order to block ion permeation, which then blocks the influx of calcium and the transmission of the nociceptive responses. Neurons located in the posterior horn of the spinal cord experience \u0277\u0277-conotoxins that, when binding to the receptors, can inhibit the release of the pro-nociceptive neurotransmitters and neuromodulators that come from the central nerve terminals of the afferent neurons. This inhibition is what ultimately can stop the transmission of pain to the person from damaged cells. Ziconotide is an inorganic version of the \u0277\u0277-conotoxin, MVIIA. This medicine is able to inhibit the release of pro-nociceptive receptors, which will then block the transmission of pain.",
            "score": 54.86250305175781
        },
        {
            "docid": "18983276_8",
            "document": "Channel blocker . Many different organic compounds can act as channel blockers despite channel specificity. Channels have evolved structures that, due to their membrane spanning regions, can discriminate between various ions or compounds. For example, some objects are too large for to fit into channels that are structurally specified to transport smaller objects, such as a potassium ion attempting to fit into a sodium channel. Conversely, some objects are too small to be properly stabilized by certain channel pores, such as a sodium ion attempting to pass through a potassium channel. In both cases, channel flux is not permitted. However, as long as a particular compound possesses adequate chemical affinity to a channel, that compound may be able to bind and block the channel pore. For example, TTX can bind and inactivate voltage-gated sodium channels, despite the fact that TTX is much larger and chemically different than sodium ions. Given the disparities in size and chemical properties between TTX and a sodium ion, this is an example of structure being used to block usually specific channels.",
            "score": 53.834739685058594
        },
        {
            "docid": "1685778_15",
            "document": "Neuropharmacology . Ion channels located on the surface membrane of the neuron allows for an influx of sodium ions and outward movement of potassium ions during an action potential. Selectively blocking these ion channels will decrease the likelihood of an action potential to occur. The drug riluzole is a neuroprotective drug that blocks sodium ion channels. Since these channels cannot activate, there is no action potential, and the neuron does not perform any transduction of chemical signals into electrical signals and the signal does not move on. This drug is used as an anesthetic as well as a sedative.",
            "score": 53.060020446777344
        },
        {
            "docid": "1938822_3",
            "document": "HERG . hERG forms the major portion of one of the ion channel proteins (the 'rapid' delayed rectifier current (\"I\")) that conducts potassium (K) ions out of the muscle cells of the heart (cardiac myocytes), and this current is critical in correctly timing the return to the resting state (repolarization) of the cell membrane during the cardiac action potential. Sometimes, when referring to the pharmacological effects of drugs, the terms \"hERG channels\" and \"I\" are used interchangeably, but, in the technical sense, \"hERG channels\" can be made only by scientists in the laboratory; in formal terms, the naturally occurring channels in the body that include hERG are referred to by the name of the electrical current that has been measured in that cell type, so, for example, in the heart, the correct name is \"I\". This difference in nomenclature becomes clearer in the controversy as to whether the channels conducting \"I\" include other subunits (e.g., beta subunits) or whether the channels include a mixture of different types (isoforms) of hERG, but, when the originally-discovered form of hERG is experimentally transferred into cells that previously lacked hERG (i.e., heterologous expression), a potassium ion channel is formed, and this channel has many signature features of the cardiac 'rapid' delayed rectifier current (\"I\"), including \"I\"'s inward rectification that results in the channel producing a 'paradoxical resurgent current' in response to repolarization of the membrane.",
            "score": 53.027549743652344
        },
        {
            "docid": "857170_42",
            "document": "Cardiac action potential . The sympathetic nervous system (nerves dominant during the bodies fight or flight response) increase heart rate (positive chronotropy), by decreasing the time to produce an action potential in the SAN. Nerves from the spinal cord release a molecule called noradrenaline, which binds to and activates receptors on the pacemaker cell membrane called \u03b21 adrenoceptors. This activates a protein, called a G-protein (s for stimulatory). Activation of this G-protein leads to increased levels of cAMP in the cell (via the cAMP pathway). cAMP binds to the HCN channels (see above), increasing the funny current and therefore increasing the rate of depolarization, during the pacemaker potential. The increased cAMP also increases the opening time of L -type calcium channels, increasing the Ca current through the channel, speeding up phase 0.",
            "score": 52.90532302856445
        },
        {
            "docid": "41564423_3",
            "document": "Local anesthetic nerve block . Local anesthetics act on the voltage-gated sodium channels that conduct electrical impulses and mediate fast depolarization along nerves. Local anesthetics also act on potassium channels, but they block sodium channels more.",
            "score": 51.99638366699219
        },
        {
            "docid": "53513088_12",
            "document": "Decarbamoylsaxitoxin . Decarbamoylsaxitoxin is a known neurotoxin, which mechanism is based on that of saxitoxin. Both namely bind to sodium channels, as shown in figure 3 Sodium channels contain negative residues at the top of their pore. These negatively charged residues are part of the filter for sodium. Decarbamoylsaxitoxin contains two guanidine substructures which can be protonated easily. Protonation of the guanidine substructures leads to a positive charge on the decarbamoylsaxitoxin and because of this positive charge the decarbamoylsaxitoxin can bind to the sodium channels. This binding to sodium channels prevents sodium passing through the channel. Because sodium passage is blocked, the channel cannot fulfill its function and it will be impossible to generate an action potential in the cell with the blocked sodium channels. There has been a study performed on which sodium channels are mainly targeted by the neurotoxin. This study showed that the neuromuscular transmission in the motor axon and the muscular membrane is targeted whereas the end-plate is left unaffected. It also showed that the atrioventicular node is the main target inside the heart. The consequences of decarbamoylsaxitoxin are paralysis and death.In vitro tests declared decarbamoylsaxitoxin more toxic as its brother saxitoxin. Although it is not entirely sure how this is caused, it can be speculated that it is caused by the alcohol group that is present on decarbamoylsaxitoxin instead of the amide group on saxitoxin. However, what can be concluded for sure is that decarbamoylsaxitoxin is converted into other compounds in the body or has trouble reaching the sodium channels. In vivo tests namely declared decarbamoylsaxitoxin half as toxic as saxitoxin.",
            "score": 51.88902282714844
        },
        {
            "docid": "50045759_14",
            "document": "Charles Antzelevitch . In the realm of acquired arrhythmias, Antzelevitch's research team was the first to recognize that the antianginal drug ranolazine blocks the electrical pathway in the heart known as the late sodium channel, an atrial-selective action that has potential benefit in the treatment of AF. With cardiac electrophysiologist Alexander Burashnikov, PhD, Antzelevitch subsequently hypothesized and then demonstrated that combining ranolazine with dronedarone, a drug with a similar action but different mechanism, can significantly suppress the occurrence of AF.",
            "score": 51.52115249633789
        },
        {
            "docid": "18037036_3",
            "document": "Pilsicainide . Pilsicainide is a drug used clinically in Japan to treat cardiac arrhythmias. It functions by blocking the fast inward movement of sodium ions through the Nav1.5 sodium channel that contributes to the rapid depolarization characteristic of phase 0 in the cardiac action potential. Pilsicainide is a pure sodium channel blocker, meaning it does not significantly affect any other cardiac channels including potassium and calcium channels. Pilsicainide binds to a common site on the sodium channel through either intracellular or extracellular application(3). The affinity of pilsicainide for the sodium channel receptor and its rate of binding are dependent on the state of the channel. It has been proven to have a greater affinity for the receptor in its inactivated state as opposed to resting or open(4), thereby following the modulated receptor hypothesis(5). Binding of pilsicainide selectively inhibits the channel(6), preventing the movement of sodium ions into the cardiac cell. This decreases the rate of depolarization of the cell membrane as well as the action potential amplitude, but has no effect on the overall duration of the action potential(6). Suppression of the depolarization rate is use-dependent(7), and therefore inhibition increases with increased stimulation. Pilsicainide also causes delayed impulse conduction through the myocardium in a dose-dependent manner(8). The effects of pilsicainide have a slow rate of onset and offset resulting in a prolonged recovery time(9). This contributes to its potent blocking activity and its classification as a class 1c antiarrhythmic agent(10). A cardiac arrhythmia includes any abnormal heartbeat and can be manifested as tachycardia, bradycardia, or other irregular rhythms. Pilsicainide has been proven successful in treating both ventricular(11) and supraventricular arrhythmias with few adverse effects(12). It is especially effective in the treatment of atrial fibrillation. Atrial fibrillation is the most common type of arrhythmia(14). It may result from various heart abnormalities or may occur spontaneously in a seemingly healthy individual(15). Atrial fibrillation is characterized by rapid, disorganized electrical impulses in the atria resulting in depolarization of only a small group of myocardial cells. This prevents the atria from undergoing coordinated contraction, instead resulting in small fibrillations of the heart muscle. Re-entry occurs when an impulse does not die after activating the heart but instead returns to the atria and causes re-excitation(16). Simultaneous re-entry of multiple impulses with short wavelengths results in atrial fibrillation(17). Impulse wavelength is the product of the conduction velocity and the effective refractory period. Pilsicainide suppresses atrial conduction velocity but also increases the effective refractory period(18). Its effects on the refractory period are significantly more substantial, and therefore pilsicainide treatment results in an increased wavelength and termination of atrial fibrillation. A single oral dose of pilsicainide effectively restores normal sinus rhythm in patients with recent-onset atrial fibrillation and a healthy left ventricle. Long-term therapy with pilsicainide is successful in treating chronic atrial fibrillation).",
            "score": 51.07296371459961
        },
        {
            "docid": "1349300_20",
            "document": "Cyclic nucleotide\u2013gated ion channel . By measuring the currents activated in excised inside-out membrane patches upon superfusion with varying ligand concentrations, the ligand sensitivity and selectivity of both endogenously and exogenously expressed CNG channels have been studied. All native CNG channels react to both cAMP and cGMP, but smaller concentrations of cGMP than of cAMP are needed to activate and open the channels. CNG channels are sharply selective between cGMP and cAMP in rods and cones, whereas in OSNs, the channels respond equally well to both ligands. CNG channels found in OSNs are much more sensitive to both cGMP and cAMP than photoreceptor CNG channels. Studies of dose response relations showed that channel activation is greatly dependent on cGMP concentration; several cGMP molecules bind to the channel in a cooperative manner. Since each subunit contains a single cNMP-binding site, and homomeric and heteromeric channels most likely form a tetrameric complex, a maximum of four ligand molecules can bind to the channel. Selectivity can be achieved by differential control of the affinity for binding of the ligand, efficacy of gating, or a combination of both. Binding affinity means how tightly cyclic nucleotides bind to the channel. Efficacy refers to the ability of ligand to activate and open the channel once it is bound. Although these processes are useful in understanding selectivity, they are inextricably coupled to each other that it is very difficult to experimentally separate one from another.",
            "score": 50.94540786743164
        },
        {
            "docid": "8497659_3",
            "document": "Nav1.7 . Na1.7 is a voltage-gated sodium channel and plays a critical role in the generation and conduction of action potentials and is thus important for electrical signaling by most excitable cells. Na1.7 is present at the endings of pain-sensing nerves, the nociceptors, close to the region where the impulse is initiated. Stimulation of the nociceptor nerve endings produces \"generator potentials\", which are small changes in the voltage across the neuronal membranes. The Na1.7 channel amplifies these membrane depolarizations, and when the membrane potential difference reaches a specific threshold, the neuron fires. In sensory neurons, multiple voltage-dependent sodium currents can be differentiated by their voltage dependence and by sensitivity to the voltage-gated sodium-channel blocker tetrodotoxin. The Na1.7 channel produces a rapidly activating and inactivating current which is sensitive to the level of tetrodotoxin. Na1.7 is important in the early phases of neuronal electrogenesis. Na1.7 activity consists of a slow transition of the channel into an inactive state when it is depolarized, even to a minor degree. This property allows these channels to remain available for activation with even small or slowly developing depolarizations. Stimulation of the nociceptor nerve endings produces \"generator potentials\", small changes in the voltage across the neuronal membranes. This brings neurons to a voltage that stimulate Na1.8, which has a more depolarized activation threshold that produces most of the transmembrane current responsible for the depolarizing phase of action potentials.",
            "score": 50.9157829284668
        },
        {
            "docid": "179962_3",
            "document": "Anticonvulsant . Conventional antiepileptic drugs may block sodium channels or enhance \u03b3-aminobutyric acid (GABA) function. Several antiepileptic drugs have multiple or uncertain mechanisms of action. Next to the voltage-gated sodium channels and components of the GABA system, their targets include GABA receptors, the GAT-1 GABA transporter, and GABA transaminase. Additional targets include voltage-gated calcium channels, SV2A, and \u03b12\u03b4. By blocking sodium or calcium channels, antiepileptic drugs reduce the release of excitatory glutamate, whose release is considered to be elevated in epilepsy, but also that of GABA. This is probably a side effect or even the actual mechanism of action for some antiepileptic drugs, since GABA can itself, directly or indirectly, act proconvulsively. Another potential target of antiepileptic drugs is the peroxisome proliferator-activated receptor alpha. The drug class was the 5th-best-selling in the US in 2007.",
            "score": 50.65769958496094
        },
        {
            "docid": "1157843_10",
            "document": "Procainamide . Procainamide works as an anti-arrhythmic agent and is used to treat cardiac arrhythmia. It induces rapid block of the batrachotoxin (BTX)-activated sodium channels of the heart muscle and acts as antagonist to long-gating closures. The block is voltage-dependent and can occur from both sides; either from the intracellular or the extracellular side. Blocking from the extracellular side is weaker than from the intracellular side because it occurs via the hydrophobic pathway. Procainamide is present in charged form and probably requires a direct hydrophobic access to the binding site for blocking of the channel. Furthermore, blocking of the channel shows a decreased voltage sensitivity, which may result from the loss of voltage dependence of the blocking rate. Due to its charged and hydrophilic form, procainamide has its effect from the internal side, where it causes blockage of voltage-dependent, open channels. With increasing concentration of procainamide, the frequency of long blockage becomes less without the duration of blockage being affected. The rate of fast blocking is determined by the membrane depolarization. Membrane depolarization leads to increased blocking and decreased unblocking of the channels. Procainamide slows the conduction velocity and increases the refractory period, such that the maximal rate of depolarization is reduced.",
            "score": 50.608154296875
        },
        {
            "docid": "463847_16",
            "document": "BK channel . Several issues arise when there is a deficit in BK channels. Consequences of the malfunctioning BK channel can affect the functioning of a person in many ways, some more life threatening than others. BK channels can be activated by exogenous pollutants and endogenous gasotransmitters carbon monoxide, nitric oxide, and hydrogen sulphide. Mutations in the proteins involved with BK channels or genes encoding BK channels are involved in many diseases. A malfunction of BK channels can proliferate in many disorders such as: epilepsy, cancer, diabetes, asthma, and hypertension. Specifically, \u03b21 defect can increase blood pressure and hydrosaline retention in the kidney. Both loss of function and gain of function mutations have been found to be involved in disorders such as epilepsy and chronic pain. Furthermore, increases in BK channel activation, through gain-of-function mutants and amplification, has links to epilepsy and cancer. Moreover, BK channels play a role in tumors as well as cancers. In certain cancers gBK, a variant ion channel called glioma BK channel, can be found. It is known that BK channels do in some way influence the division of cells during replication, which when unregulated can lead to cancers and tumors. Moreover, an aspect studied includes the migration of cancer cells and the role in which BK channels can facilitate this migration, though much is still unknown. Another reason why BK channel understanding is important involves its role in organ transplant surgery. This is due to the activation of BK channels influencing repolarization of the resting membrane potential. Thus, understanding is crucial for safety in effective transplantation.",
            "score": 50.545433044433594
        },
        {
            "docid": "9146605_4",
            "document": "Paralytic (gene) . Currently there are 117 known allele variants within the \"para\" locus, a few are mentioned below. This proteins forms a sodium-selective ion channel, that relies on an electrochemical gradient. The protein consists of four homology domains, HD1, HD2, HD3 and HD4. Each homology domain has six alpha helical segments, S1-S6. The small alpha-helical region between S5 and S6 is known as the channel pore. Mutations within this region may be responsible for ion selectivity. The cytoplasmic loop between HD3 and HD4 is responsible for fast inactivation and blocking conductance. The voltage sensor 4 in HD III is partially formed by exon L and K. The alternative splicing at this locus causes a difference in the charged current at this channel. Exon L produces 8% of the transient current, which falls to 2% when the K exon is incorporated. \"Paralytic\" encodes a protein channel which transfers sodium ions into neurons and is activated in response to changes in the voltage across a membrane to propagate an action potential. The paralytic protein has been found in the thoracic-abdominal ganglion, eye tissues and cortical regions in the brain.",
            "score": 50.50532531738281
        },
        {
            "docid": "175734_27",
            "document": "Local anesthetic . All LAs are membrane-stabilizing drugs; they reversibly decrease the rate of depolarization and repolarization of excitable membranes (like nociceptors). Though many other drugs also have membrane-stabilizing properties, not all are used as LAs (propranolol, for example). LA drugs act mainly by inhibiting sodium influx through sodium-specific ion channels in the neuronal cell membrane, in particular the so-called voltage-gated sodium channels. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Local anesthetic drugs bind more readily to sodium channels in an activated state, thus onset of neuronal blockade is faster in rapidly firing neurons. This is referred to as state-dependent blockade.",
            "score": 50.48617935180664
        },
        {
            "docid": "2917198_10",
            "document": "Neuropsychopharmacology . It has previously been known that ultimate control over the membrane voltage or potential of a nerve cell, and thus the firing of the cell, resides with the trans-membrane ion channels which control the membrane currents via the ions K, Na, and Ca, and of lesser importance Mg and Cl. The concentration differences between the inside and outside of the cell determine the membrane voltage.Precisely how these currents are controlled has become much clearer with the advances in receptor structure and G-protein-coupled processes. Many receptors are found to be pentameric clusters of five trans-membrane proteins (not necessarily the same) or \"receptor subunits\", each a chain of many amino acids. Transmitters typically bind at the junction between two of these proteins, on the parts that protrude from the cell membrane. If the receptor is of the ionotropic type, a central pore or channel in the middle of the proteins will be mechanically moved to allow certain ions to flow through, thus altering the ion concentration difference. If the receptor is of the metabotropic type, G-proteins will cause metabolism inside the cell that may eventually change other ion channels. Researchers are better understanding precisely how these changes occur based on the protein structure shapes and chemical properties.",
            "score": 50.3318977355957
        },
        {
            "docid": "22210872_19",
            "document": "Barbiturate . Further, barbiturates are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABA receptor channel is only one of several representatives. This superfamily of ion channels includes the neuronal nACh receptor channel, the 5-HT receptor channel, and the glycine receptor channel. However, while GABA receptor currents are increased by barbiturates (and other general anaesthetics), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds. For example, neuronal nAChR channels are blocked by clinically relevant anaesthetic concentrations of both thiopental and pentobarbital. Such findings implicate (non-GABA-ergic) ligand-gated ion channels, e.g. the neuronal nAChR channel, in mediating some of the (side) effects of barbiturates. This is the mechanism responsible for the (mild to moderate) anesthetic effect of barbiturates in high doses when used in anesthetic concentration.",
            "score": 50.18628692626953
        },
        {
            "docid": "2020589_23",
            "document": "G protein-gated ion channel . Atrial fibrillation (abnormal heart rhythm) is associated with shorter action potential duration and believed to be affected by the G protein-gated K channel, I. The I channel, when activated by G proteins, allows for the flow of K across the plasma membrane and out of the cell. This current hyperpolarizes the cell, thus terminating the action potential. It has been shown that in chronic atrial fibrillation there an increase in this inwardly rectifying current because of constantly activated I channels. Increase in the current results in shorter action potential duration experienced in chronic atrial fibrillation and leads to the subsequent fibrillating of the cardiac muscle. Blocking I channel activity could be a therapeutic target in atrial fibrillation and is an area under study.",
            "score": 50.09336853027344
        },
        {
            "docid": "2020589_22",
            "document": "G protein-gated ion channel . Altered cardiac regulation is common in adults diagnosed with Down syndrome and may be related to G protein-gated ion channels. The KCNJ6 gene is located on chromosome 21 and encodes for the GIRK2 protein subunit of G protein-gated K channels. People with Down Syndrome have three copies of chromosome 21, resulting in an overexpression of the GIRK2 subunit. Studies have found that recombinant mice overexpressing GIRK2 subunits show altered responses to drugs that activate G protein-gated K channels. These altered responses were limited to the sino-atrial node and atria, both areas which contain many G protein-gated K channels. Such findings could potentially lead to the development of drugs that can help regulate the cardiac sympathetic-parasympathetic imbalance in Down Syndrome adults.",
            "score": 50.02517318725586
        },
        {
            "docid": "18944450_5",
            "document": "ANK3 . The ANK3 protein associates with the cardiac sodium channel Na1.5 (). Both proteins are highly expressed at ventricular intercalated disc and T-tubule membranes in cardiomyocytes. A mutation in the Na1.5 protein blocks interaction with ANK3 binding and therefore disrupts surface expression of Na1.5 in cardiomyocytes resulting in Brugada syndrome, a type of cardiac arrhythmia.",
            "score": 50.01334762573242
        },
        {
            "docid": "1938822_7",
            "document": "HERG . Although there exist other potential targets for cardiac adverse effects, the vast majority of drugs associated with acquired QT prolongation are known to interact with the hERG potassium channel. One of the main reasons for this phenomenon is the larger inner vestibule of the hERG channel, thus providing more space for many different drug classes to bind and block this potassium channel.",
            "score": 49.96798324584961
        }
    ]
}